New funds to boost European life sciences
European investment firm LSP has closed its European life sciences fund LSP at 1 bn. Additionally, a 10bn fund of funds was greenlighted at the EU Council in Paris.
Aicuris licences antisense RNA know-how from Hybridize Therapeutics
AiCuris will pay up to 100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
BioNTech collaborates with AGC Biologics
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Council confirms European Scale-up Initiative
EU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide 10bn for late-state tech companies.
Viennese Ribbon Biolabs closes 18m Series A financing
Ribbon Biolabs has cashed in 18m in Series A financing led by Hadean Ventures
mRNA specalist Ethris raises $26m in Series B financing
German mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.
BioNTech and Pfizer evaluate Omicron-specific vaccine
Pfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.
Cytovation AS kicks-off with $20m Series A financing
Norways immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater.
Valneva vaccine neutralises Omicron variant
French-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant.
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
Swiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases